AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
March 14, 2022 07:00 ET
|
AVEO Pharmaceuticals, Inc.
– Total 2021 Net Revenue of $42.3 Million – – FOTIVDA® (tivozanib) U.S. Net Product Revenue of $38.9 Million since March 22, 2021 – – FOTIVDA U.S. Net Product Revenue of $16.8 Million for 4Q 2021,...
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
March 07, 2022 08:30 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial...
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
February 14, 2022 17:01 ET
|
AVEO Pharmaceuticals, Inc.
Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib) Long-term data from pivotal TIVO-3 study continue to...
AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference
February 03, 2022 08:00 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team...
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
January 20, 2022 08:00 ET
|
AVEO Pharmaceuticals, Inc.
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two trials in progress posters presentations for...
AVEO Oncology Highlights Recent Progress and 2022 Outlook
January 04, 2022 08:05 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022. ...
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
January 04, 2022 08:00 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial...
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
December 22, 2021 08:00 ET
|
AVEO Pharmaceuticals, Inc.
BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team...